Incorporation of patient‐reported outcomes in early‐phase clinical trials for childhood and adolescent cancer
Pediatric Blood & Cancer · 2024
DOI: 10.1002/pbc.31165 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Andrea Vilaplana und 9 weiteren Autor:innen. Beteiligte Einrichtung: Childhood Cancer and Blood Disorders Research Group, Vall d'Hebron Research Institute, Barcelona, Spain. Hauptthemen laut MEDLINE: Patient Reported Outcome Measures, Neoplasms, Quality of Life. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research, NHS funding from the Hall-Hunter Foundation to the Paediatric and Adolescent Unit, Giant Pledge.
Abstract (Originalsprache)
Introduction
The assessment of quality of life (QoL) should be one of the main objectives in paediatric clinical trials. Even though researchers, regulators and advocates support the use of patient‐reported outcomes (PROs), this has not been fully implemented. The aim of this study is to assess the measurement of QoL and the usage of PROs, palatability assessments and medication diaries in early‐phase clinical trials for childhood and adolescent cancer.
Methods
Early‐phase clinical trials for children and adolescents with cancer opened between 2005 and 2022 at the Royal Marsden Hospital (London, UK) and Vall d'Hebron University Hospital (Barcelona, Spain) were interrogated for trial characteristics and the use of QoL questionnaires, PROs, palatability assessments and medication diaries.
Results
Overall, 72 clinical trials were analysed: 12 (16.7%) evaluated QoL and eight (11.1%) evaluated PROs. Palatability was tested in 21/40 (52.5%) trials of oral drugs and 23/72 (31.9%) incorporated medication diaries. No studies mentioned patient involvement in the trial protocol. Use of PROs increased from one of 36 (2.8%) to seven of 36 (19.4%) between the first period (2005–2016) and the second period (2017–2022) ( p = .02). Implementation of medication diaries increased from seven of 36 (19.4%) to 16/36 (44.4%) in each period, respectively ( p = .02).
Conclusion
Only a minor proportion of the international/multicentric early‐phase trials evaluated included QoL/PROs and medication diaries or palatability questionnaires to help assess these, although this trend seems to be increasing over recent years. Greater implementation of QoL/PROs has the potential to improve the patient's wellbeing and facilitate symptom control, to enhance patient/parent involvement in future trial designs and to provide information for drug prioritisation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Childhood Cancer and Blood Disorders Research Group, Vall d'Hebron Research Institute, Barcelona, Spain.
- Paediatric Haematology and Oncology Division, Vall d'Hebron University Hospital, Barcelona, Spain.
- Paediatric & Adolescent Oncology Drug Development Unit, The Royal Marsden NHS Foundation Trust and Division of Clinical Studies, The Institute of Cancer Research, London, UK.
- ACCELERATE, Brussels, Belgium.
ORCID-Profile: Lucas Moreno
Förderung
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
- NHS funding from the Hall-Hunter Foundation to the Paediatric and Adolescent Unit
- Giant Pledge
- Oak Foundation
- Fight Kids Cancer (BEACON BIO project)
- Asociación Española de Pediatría
- Royal Marsden Cancer Charity
Zitieren
APA
Vilaplana, A., Morell, M., Valero-Arrese, L., Marshall, L. V., Saló, A., Crowe, T., Romero, L., de Rojas, T., Carceller, F., & Moreno, L. (2024). Incorporation of patient‐reported outcomes in early‐phase clinical trials for childhood and adolescent cancer. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31165
Vancouver
Vilaplana A, Morell M, Valero-Arrese L, Marshall LV, Saló A, Crowe T, et al. Incorporation of patient‐reported outcomes in early‐phase clinical trials for childhood and adolescent cancer. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31165
BibTeX
@article{Vilaplana2024,
author = {Vilaplana, Andrea and Morell, Mariona and Valero-Arrese, Lorena and Marshall, Lynley V and Saló, Anna and Crowe, Tracey and Romero, Laura and de Rojas, Teresa and Carceller, Fernando and Moreno, Lucas},
title = {Incorporation of patient‐reported outcomes in early‐phase clinical trials for childhood and adolescent cancer},
journal = {Pediatric Blood & Cancer},
year = {2024},
doi = {10.1002/pbc.31165}
}
EUVIMED